Sunstone Therapies

Sunstone Therapies is a cutting-edge startup excelling in the research and delivery of psychedelic therapies for individuals grappling with complex mental health challenges. The company is at the forefront in providing psychedelic-assisted therapy in medical settings, with a current emphasis on clinical trial development and execution, gradually moving towards clinical delivery upon therapy approval. Sunstone's core objective is to alleviate the emotional suffering of individuals affected by cancer and complex mental health challenges and disorders, ultimately making safe and effective psychedelic-assisted therapy widely accessible. The company's approach revolves around the belief that health encompasses not just the absence of illness, but also emotional, social, and spiritual well-being. In the last 12 months, Sunstone has treated more patients with PAT (excluding ketamine) within a clinical setting than any other organization worldwide. The delivery of psychedelic therapies is a multifaceted process necessitating substantial expertise and capabilities in logistics, infrastructure, training, and clinical care. Sunstone adopts a patient-centric model rooted in the cancer care paradigm, leveraging the team's extensive experience in oncology to ensure operational excellence in providing intricate, multi-faceted care at scale. Additionally, the company offers training and education in PAT and focuses on all aspects of clinic design and delivery, including digital platforms, cost modeling, and quality of care. Founded in 2022 and headquartered in the United States, Sunstone Therapies has yet to disclose its latest investment details and investors. This pioneering Health Care startup presents promising opportunities for venture capital firms seeking to invest in the rapidly advancing field of psychedelic therapy.